Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's heart disease and bone tests:

This article was originally published in Clinica

Executive Summary

Roche Diagnostics has received US FDA 510(k) clearances for a new heart disease risk assay and an osteoporosis monitoring test. In heart disease, the clearance expand's the application of Roche's Elecsys proBNP test to use in the assessment of stable coronary artery disease risk. The test is already cleared to help diagnose individuals suspected of congestive heart failure (CHF), and as a marker of risk for acute coronary syndrome (ACS) and CHF. Roche claims its assay is the first natriuretic peptide test to receive FDA clearance for the new indication. According to the firm, over 192 million people in major countries have a high risk of developing cardiac events due to stable coronary artery disease. For osteoporosis, the FDA has cleared the firm's Elecsys N-MID test for osteocalcin, a protein found in the bone and in blood serum, which is an indicator of bone formation.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel